| 000 | 01079 a2200325 4500 | ||
|---|---|---|---|
| 005 | 20250513092506.0 | ||
| 264 | 0 | _c19960822 | |
| 008 | 199608s 0 0 eng d | ||
| 022 | _a0140-6736 | ||
| 024 | 7 |
_a10.1016/s0140-6736(96)24030-9 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGore, M | |
| 245 | 0 | 0 |
_aTumour marker levels during marimastat therapy. _h[electronic resource] |
| 260 |
_bLancet (London, England) _cJul 1996 |
||
| 300 |
_a263-4 p. _bdigital |
||
| 500 | _aPublication Type: Comment; Letter | ||
| 650 | 0 | 4 |
_aCA-125 Antigen _xblood |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xpharmacology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aHydroxamic Acids |
| 650 | 0 | 4 |
_aMetalloendopeptidases _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aOvarian Neoplasms _xblood |
| 650 | 0 | 4 | _aRetrospective Studies |
| 700 | 1 | _aA'Hern, R | |
| 700 | 1 | _aStankiewicz, M | |
| 700 | 1 | _aSlevin, M | |
| 773 | 0 |
_tLancet (London, England) _gvol. 348 _gno. 9022 _gp. 263-4 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0140-6736(96)24030-9 _zAvailable from publisher's website |
| 999 |
_c8682036 _d8682036 |
||